Completed PHASE2 INTERVENTIONAL 1-arm NCT00763763

Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive (AFR07)

Study to Evaluate Efficacy and Safety of Glivec® in Combination With Vincristine and Dexamethasone in Patients With Lymphoid Blast Crisis CML or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Relapse or Refractory

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Blast Crisis Leukemia, Lymphocytic, Acute Leukemia, Myeloid, Chronic Philadelphia Chromosome

Interventions Dexamethasone Imatinib mesylate Interferon Vincristine

Updated 5 times since 2017 Last updated: Oct 4, 2011 Started: Dec 31, 2004 Primary completion: Oct 31, 2007 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00763763, this PHASE2 trial focuses on Blast Crisis and Leukemia, Lymphocytic, Acute and remains completed. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France